Ken Griffin Idera Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.23 - $0.43 $15,180 - $28,380	-66,002 Reduced 56.74%	50,318 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.53 $19,521 - $27,227	-51,373 Reduced 30.64%	116,320 $44,000
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.74 $40,629 - $93,955	126,967 Added 311.76%	167,693 $77,000
Q1 2022 May 16, 2022	SELL	$0.41 - $0.7 $70,147 - $119,764	-171,092 Reduced 80.77%	40,726 $20,000
Q4 2021 Feb 14, 2022	BUY	$0.53 - $1.03 $84,334 - $163,895	159,122 Added 301.96%	211,818 $120,000
Q3 2021 Nov 15, 2021	SELL	$1.0 - $1.18 $102,062 - $120,433	-102,062 Reduced 65.95%	52,696 $54,000
Q2 2021 Aug 16, 2021	SELL	$1.01 - $1.58 $64,263 - $100,530	-63,627 Reduced 29.14%	154,758 $185,000
Q1 2021 May 17, 2021	BUY	$1.23 - $5.98 $203,352 - $988,655	165,327 Added 311.6%	218,385 $284,000
Q4 2020 Feb 16, 2021	BUY	$2.09 - $5.18 $77,572 - $192,260	37,116 Added 232.82%	53,058 $194,000
Q3 2020 Nov 16, 2020	BUY	$1.71 - $2.68 $27,260 - $42,724	15,942 New	15,942 $34,000
Q2 2020 Aug 14, 2020	SELL	$1.23 - $2.12 $14,601 - $25,166	-11,871 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.06 - $2.15 $19,389 - $39,327	-18,292 Reduced 60.64%	11,871 $16,000
Q4 2018 Feb 14, 2019	BUY	$2.77 - $9.38 $83,551 - $282,928	30,163 New	30,163 $83,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.